18 research outputs found

    The effect of R1507 on cell proliferation of NB and MB cells.

    No full text
    <p>A panel of NB cell lines (A) and MB cell lines (B) were incubated with increasing concentrations of the antibody R1507 inhibiting the IGF-1R in serum-containing medium. Cell viability was assessed using the MTS assay after 2 days. The data represent the mean with SD from at least 6 replicates and 3 independent experiments.</p

    Targeted therapies in medulloblastoma.

    No full text
    <p>The MB cell lines Daoy (A) and UW228 (B) were incubated with increasing concentrations of the EGFR inhibitors gefinitib or erlotinib, the Abl inhibitor imatinib, the IGF-1R inhibitor NVP-AEW541 and the mTOR inhibitor rapamycin. Cell proliferation was assessed using the MTS assay after 72 h. The data represent the mean of 6 replicates with SD from 3 independent experiments.</p

    Cell proliferation of NB and MB cells after inhibition of the PI3K p110α.

    No full text
    <p>A panel of NB cell lines (A) and MB cell lines (B) were incubated with increasing concentrations of the specific pharmacological PI3K p110α inhibitor PIK75 in serum-containing medium. Cell viability was assessed using the MTS assay after 2 (NB) or 3 (MB) days. The data represent the mean with SD from at least four replicates and 1–3 independent experiment.</p

    Additive/sensitization effects after combinatorial treatment with R1507 and chemotherapy in MB cells.

    No full text
    <p>The MB cell lines PFSK (A), UW228 (B) and DAOY (C) grown in serum-containing medium were incubated with increasing concentrations of cisplatin in presence or absence of the IGF-1R antibody R1507 (25 µg/ml or 50 µg/ml). Cell proliferation was assessed using the MTS assay after 48 h. The data represent the mean of 6 replicates with SD from 3 independent experiments.</p

    Effects of R1507 in combination with targeted therapies in medulloblastoma.

    No full text
    <p>The R1507-insensitive cell line DAOY was incubated with increasing concentrations of the EGFR inhibitor gefinitib (A), the Abl inhibitor imatinib (B), the IGF-1R inhibitor NVP-AEW541 (C) and the mTOR inhibitor rapamycin (D) in presence or absence of the IGF-1R antibody R1507. Cell proliferation was assessed using the MTS assay after 72 h. The data represent the mean of 6 replicates with SD from 3 independent experiments.</p

    Treatment of NB cells with R1507 or PIK75 in presence of chemotherapy results in additive effects.

    No full text
    <p>NB cells grown in serum-containing medium were incubated with the IGF-1R antibody R1507 (0.1 μg/ml) (A) or the PI3K inhibitor PIK75 (0.05 μM) (B+C) in presence or absence of cisplatin (1 μM), etoposide (1 μM), or doxorubicin (0.1 μM). Cell proliferation was assessed using the MTS assay after 48 h. The data represent the mean of 8 replicates with SD from 3 independent experiments. (*p<0.05).</p

    Sensitivity to R1507 and PIK75, and presence of IGFR in neuroblastoma cell lines LAN1 and LAN1R, a LAN1 cell line resistant to doxorubicin.

    No full text
    <p>(A) R1507 treatment for 48 hours. (B) PIK75 treatment for 48 hours. Error bars represent ±S.D. of means from 3 experiments, each with 3 replicates, except that there was only one experiment with 500 nM PIK75 in B. (C) Western blot analysis of components of the IGF-1R/PI3K pathway in LAN1 and LAN1R whole cell extracts. Src was used as internal loading control. (D) Transfection of LAN1 cells with siRNA targeting the IGF-1R (non-targeting siRNA was used as control. Expression levels of the IGF-1R were assessed by Western blot analysis in LAN1 whole cell lysates after 96 h). Cell proliferation in LAN1 cells upon IGF-1R silencing was assessed in absence or presence of R1507 after 96h by MTS. (*p<0.05).</p

    Apoptosis upon PI3K inhibition.

    No full text
    <p>(A+B) The NB cell lines LAN1 (A, left panel; B, left panel) and SH-SY5Y (B, right panel) as well as the MB cell line PFSK (A, right panel) grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110α inhibitor PIK75 and the IGF-1R antibody R1507, or cisplatin. After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and Western blotting for the proteins indicated. (C) The NB cell line WAC2 grown in serum-containing medium was incubated with increasing concentrations of the PI3K p110α inhibitor PIK75. Caspase 3/7 activity was assessed using the Caspase 3/7 Glo assay after 48 h.</p

    PI3K and IGF-1R inhibition impair receptor activation and downstream signaling.

    No full text
    <p>The NB cells SH-SY5Y (A), LAN1 (B); WAC2 (C) and the MB cells PFSK (D) grown in serum-containing medium were incubated with increasing concentrations of the PI3K p110α inhibitor PIK75 and the IGF-1R antibody R1507. After 24 hours the cells were harvested and whole cell lysates analysed by SDS-PAGE and Western blotting for the proteins indicated. Serum-starved DAOY (E) or LAN1 (F) cells were pre-treated with vehicle or R1507 at the concentrations indicated for 1h and stimulated with IGF-1 (50 ng/ml or 100 ng/ml) for 10 min at 37°C. Cell lysates were analysed by SDS-PAGE and Western Blot for phosphorylated IGF-1R beta and total receptor.</p
    corecore